“In-silico Design and Development of Novel Hydroxyurea Lipid Drug Conjugates for Breast Cancer Therapy Targeting PI3K/AKT/mTOR Pathway”

Abstract

Hydroxyurea (HU) has shown promise in breast cancer treatment, but its hydrophilic nature limits its efficacy. Therefore, conjugating HU with lipids could increase its liphophilicity and improve its cellular uptake, leading to increased efficacy and reduced toxicity. The PI3K/Akt/mTOR pathway is an attractive therapeutic target in cancer not only because it is the second most frequently altered pathway after p53, but also because it serves as a convergence point for many stimuli. The aim of this study is to design and develop novel hydroxyurea lipid drug conjugates for breast cancer therapy targeting the PI3K/Akt/mTOR pathway using in-silico and in-vitro approaches. The conjugates are designed and docked with the proteins selected for each target like PI3K (PDB ID;2JDO), AKT (PDB ID;3APF), mTOR (PDB ID;4JST). The conjugates with higher docking scores are taken for ADME studies and molecular dynamics. Stearic, lauric, palmitic, myristic and linolenic acids have been used for the conjugation. The conjugates are synthesized and characterized. The HLB calculation and partition coefficient are carried out to find the improvement in liphophilicity of the conjugates compared to hydroxyurea. Finally, the in-vitro cytotoxicity studies are performed with MCF -7 cell lines and the compound HU-MA (hydroxyurea with myristic acid) with low IC₅₀ is considered as the compound having good activity with compound code. These conjugates have been shown to have improved drug solubility and better cellular uptake compared to free hydroxyurea, which can increase drug efficacy.

Key words

breast cancer - hydroxyurea - lipid conjugates - fatty acids - lipophilicity.

Publikationsverlauf

Eingereicht: 24. August 2023

Angenommen: 06. November 2023

Artikel online veröffentlicht:
11. Januar 2024

• References

• 1 Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P. Breast cancer. Nat Rev Dis Primers 2019; 5: 66
• 2 Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they?. Mol Oncol 2010; 4: 192-208
• 3 Jemal A, Center MM, DeSantis C, Ward EM. Global Patterns of Cancer Incidence and Mortality Rates and Trends | Cancer Epidemiology, Biomarkers & Prevention | American Association for Cancer Research [Internet]. [cited 2023 Jul 12]. Available from https://aacrjournals.org/cebp/article/19/8/1893/68607/Global-Patterns-of-Cancer-Incidence-and-Mortality
• 4 Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: An overview. Journal of Advanced Pharmaceutical Technology & Research 2010; 1: 109
• 5 Yadong Cui, Maura K, Whiteman, Jodi A. Flaws, Patricia Langenberg, Katherine H. Tkaczuk, Trudy L.Bush Body mass and stage of breast cancer at diagnosis - Cui - 2002 - International Journal of Cancer - Wiley Online Library [Internet]. [cited 2023 Apr 29]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.10209
• 6 Brugge J, Hung M-C, Mills GB. A New Mutational aktivation in the PI3K Pathway. Cancer Cell 2007; 12: 104-107
• 7 Agarwal R, Carey M, Hennessy B, Mills GB. PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 2010; 11: 615-628
• 8 Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo W-L, Davies M. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer research 2008; 68: 6084-6091
• 9 Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501
• 10 Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells | SpringerLink [Internet]. [cited 2023 Apr 29]. Available from: https://link.springer.com/article/10.1186/s12885-016-3038-y
• 11 Bajer MM, Kunze MM, Blees JS, Bokesch HR, Chen H, Brauß TF. Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor. Biochemical Pharmacology 2014; 88: 313-321
• 12 Ma P, Rahima Benhabbour S, Feng L, Mumper RJ. 2’-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. Cancer Lett 2013; 334: 253-262
• 13 El-Gowily AH, Loutfy SA, Ali EMM, Mohamed TM, Mansour MA. Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals (Basel) 2021; 14: 254
• 14 Zaro JL. Lipid-based drug carriers for prodrugs to enhance drug delivery. AAPS J 2015; 17: 83-92
• 15 De Angel RE, Blando JM, Hogan MG, Sandoval MA, Lansakara-P DSP, Dunlap SM. Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model. Cancer Biol Ther 2013; 14: 357-364
• 16 Wonganan P, Lansakara-P DSP, Zhu S, Holzer M, Sandoval MA, Warthaka M. Just Getting Into Cells is Not Enough: Mechanisms Underlying 4-(N)-Stearoyl Gemcitabine Solid Lipid Nanoparticle’s Ability to Overcome Gemcitabine Resistance Caused by RRM1 Overexpression. J Control Release 2013; 169: 17-27
• 17 Perkins WR, Ahmad I, Li X, Hirsh DJ, Masters GR, Fecko CJ. Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int J Pharm 2000; 200: 27-39
• 18 Musiałek MW, Rybaczek D. Hydroxyurea—The Good, the Bad and the Ugly. Genes. 2021; 12: 1096
• 19 Kapor S, Čokić V, Santibanez JF. Mechanisms of Hydroxyurea-Induced Cellular Senescence: An Oxidative Stress Connection?. Oxid Med Cell Longev 2021; 2021: 7753857
• 20 Singh A, Xu Y-J. The Cell Killing Mechanisms of Hydroxyurea. Genes. 2016; 7: 99
• 21 Marahatta A, Ware RE. Hydroxyurea: Analytical techniques and quantitative analysis. Blood Cells Mol Dis 2017; 67: 135-142
• 22 Xu H, Tu X, Fan G, Wang Q, Wang X, Chu X. Adsorption properties study of boron nitride fullerene for the application as smart drug delivery agent of anti-cancer drug hydroxyurea by density functional theory. Journal of Molecular Liquids 2020; 318: 114315
• 23 Harismah K, Sain DK, Al-Owaidi MF, Zandi H, Saimmai A. Assessing a BN-Doped Graphene for the Drug Delivery of Hydroxyurea Anticancer. Biointerface Research in Applied Chemistry 2023; 13
• 24 PKM Rajendra, BSS nidamanuri, AK Sawroop, SK Janani,S Jubie. Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach - ScienceDirect [Internet]. [cited 2023 Aug 2]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1773224723001223
• 25 Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001; 7: 3229-3238
• 26 Chhikara BS, Mandal D, Parang K. Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate. J Med Chem 2012; 55: 1500-1510
• 27 Ohwada J, Ebiike H, Kawada H, Tsukazaki M, Nakamura M, Miyazaki T. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Lett 2011; 21: 1767-1772
• 28 Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene. 2005; 24: 7493-7501
• 29 Xie X-X, Li H, Wang J, Mao S, Xin M-H, Lu S-M. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity. Bioorganic & Medicinal Chemistry 2015; 23: 6477-6485
• 30 Chaube UJ, Rawal R, Jha AB, Variya B, Bhatt HG. Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer. Bioorganic Chemistry 2021; 106: 104501
• 31 Kacper B Rogala, Xin Gu, Jibril F Kedir,Monther Abu-Remailhe Structural basis for the docking of mTORC1 on the lysosomal surface | Science [Internet]. [cited 2023 Jul 5]. Available from: https://www.science.org/doi/full/10.1126/science.aay0166
• 32 A Daina, O Michielin, V Zoete SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules | Scientific Reports [Internet]. [cited 2023 Jul 4]. Available from: https://www.nature.com/articles/srep42717
• 33 Phytochemical and in-vitro Biological Investigation of Indian Tra…: Ingenta Connect [Internet]. [cited 2023 Jul 20]. Available from: https://www.ingentaconnect.com/content/ben/cdrr/2023/00000015/00000001/art00007
• 34 Patnaik SK, Swaroop AK, Naik MR, Selvaraj J, Chandrasekar MJN. Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2. Drug Res (Stuttg) 2023; 73: 341-348
• 35 B. S. N, P. K. KN, Akey KS, Sankaran S, Raman RK, Natarajan J. Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach. Journal of Biomolecular Structure and Dynamics. 2023; 0: 1–27
• 36 Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors: Journal of Biomolecular Structure and Dynamics: Vol 36, No 12 [Internet]. [cited 2023 Jul 4]. Available from: https://www.tandfonline.com/doi/abs/10.1080/07391102.2017.1384401
• 37 Gadhave A. Determination of Hydrophilic-Lipophilic Balance Value 2014; 3: 573–575
• 38 Eleonore Coppens, Didier Desmaele, Julie Mougin, Saddrine Tussaeu-Nenez, Patrick Couvreur and Simona Mura. Gemcitabine Lipid Prodrugs: The Key Role of the Lipid Moiety on the Self-Assembly into Nanoparticles | Bioconjugate Chemistry [Internet]. [cited 2022 Dec 3]. Available from: https://pubs.acs.org/doi/10.1021/acs.bioconjchem.1c00051
• 39 Coppens E, Desmaële D, Naret T, Garcia-Argote S, Feuillastre S, Pieters G. Gemcitabine lipid prodrug nanoparticles: Switching the lipid moiety and changing the fate in the bloodstream. Int J Pharm 2021; 609: 121076
• 40 Rebecca Simstein, Matthew Burow, Amanda Parker, Christopher Weldon, Barbara Beckman, Apoptosis, Chemoresistance, and Breast Cancer: Insights From the MCF-7 Cell Model System - 2003 [Internet]. [cited 2023 Jul 5]. Available from: https://journals.sagepub.com/doi/abs/10.1177/153537020322800903
• 41 Andrés A, Rosés M, Ràfols C, Bosch E, Espinosa S, Segarra V. Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts. European Journal of Pharmaceutical Sciences 2015; 76: 181-191
• 42 Morikawa G, Suzuka C, Shoji A, Shibusawa Y, Yanagida A. High-throughput determination of octanol/water partition coefficients using a shake-flask method and novel two-phase solvent system. Journal of Pharmaceutical and Biomedical Analysis 2016; 117: 338-344
• 43 Aziz SW, Aziz MH. Major Signaling Pathways Involved in Breast Cancer. In: Ahmad A, editor. Breast Cancer Metastasis and Drug Resistance: Progress and Prospects [Internet]. New York, NY: Springer; 2013. [cited 2023 May 4]. p. 47-64 Available from: https://doi.org/10.1007/978-1-4614-5647-6_4
• 44 Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 2017; 3: 509-515
• 45 Shrivastava S, Kulkarni P, Thummuri D, Jeengar MK, Naidu VGM, Alvala M. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. Apoptosis. 2014; 19: 1148-1164
• 46 Da’i M, Wahyuni AS, Wikantyasning ER, Maryati, Mirzaei M. Insights into the Delivery of Hydrea Anticancer Drug by the Assistance of an Oxidized Silicon Carbide Nanocage. Biointerface Research in Applied Chemistry 2023; 13: 497
• 47 Harismah K, Hassan A, Hamid OT, Saadoon MA, Zandi H. Drug Delivery Assessments of Hydroxyurea Anticancer by an Epoxy-Decorated Fullerene Cage. Biointerface Research in Applied Chemistry 2023; 13